Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2

Clinical trial NCT01123083 · COMPLETED

Trial details

NCT number: NCT01123083
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Diabetes Mellitus, Type 1

Start date: 2010-05-17
Primary completion: 2012-03-09
Enrollment: 179

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.